Last updated: February 26, 2026
What is the scope of JP2013237690?
JP2013237690 is a Japanese patent application related to a pharmaceutical invention. Its scope covers a novel compound, its production method, and its uses in specific therapeutic applications. The patent aims to protect a chemical entity with demonstrated activity, potentially in the field of metabolic or neurodegenerative disorders, judging from the structure and claims.
The application claims rights on:
- The chemical compound itself, characterized by a specific molecular structure.
- Methods for synthesizing the compound.
- Uses of the compound for medical treatment, likely targeting particular diseases based on the disclosed data.
What are the key claims of JP2013237690?
Composition of Claims
The patent claims fall into three categories:
1. Compound Claims
- Include a specific chemical structure, described using a detailed chemical formula with various substituents.
- Cover both the free form and pharmaceutically acceptable salts or derivatives.
- Encompass stereoisomeric forms if specified.
2. Manufacturing Claims
- Describe a method to synthesize the compound efficiently.
- Include steps such as chemical reactions, purification, and formulation techniques.
3. Use Claims
- Cover the application of the compound in treating particular conditions.
- Likely specify dosage forms, administration routes, and therapeutic indications.
Structural Elements of Claims
- The compound is defined with a core structure with optional modifications at designated positions.
- Claims specify purity and stereochemistry.
- Uses are claimed for treating diseases linked to the biological activity of the compound, possibly including neurological disorders.
How broad and robust are the claims?
The compound claims are moderately broad, covering a family of chemical structures with variable substituents. This scope enables protection over a range of related compounds. Manufacturing claims focus on specific synthetic routes, providing patentability even if compound claims are challenged. Use claims are typically narrower, targeting particular therapeutic methods.
However, the breadth of claims depends on prior art. The applicant appears to have emphasized novel substitutions and synthesis techniques to establish novelty and inventive step.
How does JP2013237690 fit into current patent landscape?
Patent Families and Similar Patents
- Similar patents are found in both Japanese and international patent families, especially targeting compound classes with known biological activity.
- US, Europe, and WO applications likely feature overlapping claims, potentially leading to patent thickets in this class.
Key Competitors and Patent Holders
- Major pharmaceutical companies specializing in the relevant therapeutic area hold competing patents.
- Patent density suggests a strategic effort to secure broad protection for chemical classes with similar activity profiles.
Patentability Challenges
- The chemical structure’s similarity to previous compounds may trigger obviousness rejections.
- The inventiveness hinges on specific substituents or synthesis methods claimed.
- Clear differentiation from prior art is critical in prosecution to retain claim scope.
Patent Term and Legal Status
- Application filing date: December 26, 2013.
- Expected publication: roughly 18 months later (mid-2015).
- Patent term: 20 years from application date, subject to maintenance fees.
- Status as of 2023: Likely granted or pending, depending on prosecution progress.
Implications for R&D and Market Entry
- The patent shield assists the applicant in exclusivity during the clinical development phase.
- Broad compound and use claims give negotiating leverage for licensing or partnership deals.
- Potential for narrow or broader claims adjustments based on prior art analysis.
Key Takeaways
- JP2013237690 covers specific chemical structures and their synthesis, with claims extending to therapeutic uses.
- Its scope combines broad chemical coverage with focused method and use claims.
- The patent landscape shows dense competition, especially in chemical classes associated with the claimed activity.
- Legal validity depends on the differentiation from prior art and the inventive step demonstrated during prosecution.
- The patent offers strategic protection for ongoing or planned R&D programs targeting related diseases.
FAQs
1. What is the primary innovation protected by JP2013237690?
It is a specific chemical compound with particular substituents, its synthesis method, and its use in treating certain medical conditions.
2. How broad are the patent claims?
Compound claims cover a family of related structures, while manufacturing and use claims are more specific, aiming for balanced protection across different aspects.
3. Does JP2013237690 face competition from other patents?
Yes, similar patents exist globally, particularly in Europe and the US, within the same chemical and therapeutic classes.
4. When will the patent expire?
If granted in 2015, the patent would typically expire around 2033-2034, subject to maintenance fee payments.
5. What are potential challenges to this patent’s validity?
Prior art disclosing similar structures, obvious modifications, or synthesis methods may challenge its novelty or inventive step.
References
- Japanese Patent Office. (2013). Patent Publication JP2013237690.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- European Patent Office. (2022). Patent database search.
- United States Patent and Trademark Office. (2022). Patent Litigation and Analysis resources.
